Most Popular

Anti-Rheumatic Therapies for COVID-19 Infection

Save

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial.

More Rheumatology Fellow Advice from the Mentors

Save

Many speeches on success often share the same insight, “I had to turn down a lot of good advice and make a lot of mistakes to get to where I am today”.

Mistakes are to be encouraged as they will establish future certainty.

Low Risk of COVID in Biologic Treated Rheum Patients

Save

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Save

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow.

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Save

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Wisdom for New Rheumatology Fellows

Save

Congratulations on choosing the greatest profession, one equally dedicated to both science and patient care.

IL-17 Superior to TNF Inhibition in Psoriatic Arthritis

Save

A one year head-to-head (H2H) trial has shown ixekizumab (IXE) to be superior to adalimumab (ADA) in psoriatic arthritis (PsA); for both skin and articular outcomes.

Steroids and Tocilizumab in Cytokine Storm Syndrome

Save

A recent study from the Netherlands has shown that patients with severe COVID-19-associated cytokine storm syndrome (CSS)  with high dose steroids and tocilizumab had a faster recovery, less need for invasive mechanical ventilation and fewer deaths when compared to CSS patients receiving supporti

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Save

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients wer

RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)

Save

Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.

Rapid Loss of SARS-CoV-2 Antibodies in Mild Disease

Save

According to a small, observational study out of UCLA published as correspondence in the NEJM on July 21, 2020, those with mild COVID-19 symptoms showed an approximate antibody half-life of 73 days.

Fighting Hydroxychloroquine Misinformation

Save

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it.”.

PRIME Cells Predicting Rheumatoid Arthritis Flares

Save

The current issue of NEJM reports a novel cell type that may be used to identify rheumatoid arthritis (RA) patients who may flare. 

Colchicine Benefits COVID-19 Patients

Save

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Extrapulmonary Manifestations of COVID-19

Save

A new article in Nature Medicine delineates how our understanding of COVID-19 infection has evolved over time, such that the infection outomes may be worsened by extrapulmonary manifestations; notably thrombotic, cardiac, renal, gastrointestinal hepatic, neurologic, and other complicatio

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Save

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

GI Perforations with Tocilizumab Greater than Other Biologics

Save

A study from a Swedish population shows the real-world risk of gastrointestinal (GI) perforations in rheumatoid arthritis (RA) patients taking biologics finds that the risk was greatest in RA patients taking tocilizumab (TCZ), compared with RA patient taking tumour necrosis factor inhibitors (TNF

Long-Term Rituximab in ANCA-Associated Vasculitis

Save

The Annals of Internal Medicine reports that biannual rituximab infusions over 18 months was effective at maintaining remission in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Save

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  

The Burden of Gout

Save

Danve and Neogi have an editorial in the current Arthritis & Rheumatology about the burden of gout that affects 41 million adults worldwide, according to the Global Burden of Disease Study 2017 (GBD 2017) also published in the same issue.